Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma-Reference-Cited by-同舟云学术

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Published:2021-06-01 Issue:6 Volume:7 Page:862
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Landgren Ola¹²,Hultcrantz Malin¹,Diamond Benjamin¹,Lesokhin Alexander M.¹,Mailankody Sham¹,Hassoun Hani¹,Tan Carlyn¹,Shah Urvi A¹,Lu Sydney X.¹,Salcedo Meghan¹,Werner Kelly¹,Rispoli Jenna¹,Caple Julia¹,Sams Allison¹,Verducci Dennis¹,Jones Katie¹,Concepcion Isabel¹,Ciardello Amanda¹,Chansakul Aisara¹,Schlossman Julia¹,Tavitian Elizabet¹,Shekarkhand Tala¹,Harrison Angela¹,Piacentini Casey¹,Rustad Even H.¹,Yellapantula Venkata¹,Maclaughlan Kylee¹,Maura Francesco¹²,Landau Heather J.³,Scordo Michael³,Chung David J.³,Shah Gunjan³,Lahoud Oscar B.³,Thoren Katie⁴,Murata Kazunori⁴,Ramanathan Lakshmi⁴,Arcila Maria E.⁵,Ho Caleb⁴,Roshal Mikhail⁵,Dogan Ahmet⁵,Derkach Andriy⁶,Giralt Sergio A.³,Korde Neha¹

Affiliation:

1. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

2. Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida

3. Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

4. Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York

6. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2778195/jamaoncology_landgren_2021_oi_210006_1623352015.96701.pdf

Reference26 articles.

1. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.;Engelhardt;Haematologica,2014

2. Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline.;Mikhael;J Clin Oncol,2019

3. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.;Moreau;Ann Oncol,2017

4. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.;Kumar;Blood,2012

5. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.;Richardson;Blood,2010

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating early intervention in smoldering myeloma clinical trials: a systematic review;The Oncologist;2024-09-05

2. Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma;2024-09-04

3. Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma;Cancers;2024-08-23

4. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma;Blood;2024-08-15

5. Multiple myeloma and infections in the era of novel treatment modalities;Leukemia Research;2024-08